PERCORTEN by Novartis is clinical pharmacology: desoxycorticosterone pivalate (docp), like other adrenocorticoid hormones, is thought to act by controlling the rate of synthesis of proteins. First approved in 1942.
Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
PERCORTEN (desoxycorticosterone pivalate/DOCP) is a long-acting mineralocorticoid ester administered as an intramuscular microcrystalline depot pellet for treatment of hypoadrenocorticism in animals. It mimics natural aldosterone by increasing renal tubular sodium reabsorption, reducing potassium excretion, and expanding extracellular fluid volume to prevent hypotensive shock and pre-renal azotemia. The drug works by binding cytoplasmic receptor proteins, forming a steroid-receptor complex that translocates to the nucleus to modulate gene transcription and protein synthesis.
Product is approaching loss of exclusivity with minimal competitive pressure (30%), signaling potential downsizing of the brand team and transition to lifecycle management mode.
CLINICAL PHARMACOLOGY: Desoxycorticosterone pivalate (DOCP), like other adrenocorticoid hormones, is thought to act by controlling the rate of synthesis of proteins. It reacts with receptor proteins in the cytoplasm to form a steroid-receptor complex. This complex moves into the nucleus, where it…
Worked on PERCORTEN at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on PERCORTEN offers limited near-term career growth given the LOE approaching lifecycle stage and minimal linked job openings (0). Roles remaining will focus on market defense, generic preparation, and regulatory compliance rather than expansion or innovation.